Henlius and Sandoz partner to co‑develop up to ten biosimilar mAb and ADC assets, aiming to accelerate global market access and revenue generation
Executive summary: Henlius and Sandoz entered a strategic collaboration to develop up to ten proposed monoclonal antibody and antibody‑drug conjugate biosimilar assets, with most programs at early stages. The partnership combines Henlius’s early‑stage biosimilar candidates with Sandoz’s global commercial reach, potentially speeding up market entry and generating milestone‑based revenue for Henlius.
Who is involved: Henlius (China‑based biotech) and Sandoz (Novartis generics division).
Likely next: Henlius will advance the candidates toward IND submission, triggering milestone payments from Sandoz as defined in the initial arrangement.
Henlius, a Chinese biotech, and Sandoz, the generics division of Novartis, have announced a strategic collaboration to jointly develop as many as ten monoclonal antibody and antibody‑drug conjugate biosimilar candidates. Most of the programs are in early development, with Henlius expected to receive invoiced payments tied to milestones. The deal expands Sandoz’s biosimilar pipeline while giving Henlius access to global commercialization expertise and resources.
Timeline
- — Henlius and Sandoz Enter Strategic Collaboration to Unlock Global Value of Biosimilars Platform (PR Newswire)
Sources
- Henlius and Sandoz Enter Strategic Collaboration to Unlock Global Value of Biosimilars Platform — PR Newswire
Related cases
- Novartis reports positive trial results for a new multiple sclerosis therapy with reduced liver toxicity
- Akeso’s 2026 interim results show record‑high drug sales and progress on its IO 2.0 strategy, advancing bispecific ADCs in oncology, immunology and Alzheimer’s
- Akeso's B7‑H3 ADC AK157D1 gains Phase I clearance, adding a third differentiated candidate to its oncology pipeline
- Akeso advances its IO2.0/ADC2.0 strategy with first patient dosed in Phase II trial of AK146D1 combined with ivonescimab for breast cancer
- GlycoNex initiates first-in-human Phase I trial of its glycan-targeted ADC GNX1021 in Japan
- Akeso initiates first‑in‑human trial of its HER3‑targeted ADC combined with Ivonescimab in lung cancer, advancing its IO2.0+ADC2.0 pipeline